GLP-1 Lawsuit Timeline — June 2026 Updates

Judge Karen Marston has scheduled a Science Day for June 2, 2026 in the GLP-1 NAION vision loss MDL. Both sides will present non-adversarial scientific evidence on the NAION causation questions. This is a critical milestone — the judge uses Science Day testimony to understand the science before ruling on Daubert motions that determine which expert evidence reaches trial. A strong Science Day for plaintiffs accelerates the path to bellwether trials significantly.

The MDL judge issued Case Management Order No. 17 establishing the fee structure for the GLP-1 litigation. Of any gross monetary recovery — from settlements, judgments, or other awards — 9% goes to the GLP-1 Fee Fund compensating lead counsel for work that benefits all MDL participants, and 2% goes to the GLP-1 Expense Fund covering discovery, expert consultations, and other litigation expenses. Issuing a fee order signals the court is preparing for eventual monetary outcomes.

Legal analysts are now publishing settlement value projections for GLP-1 litigation. Top-tier cases involving permanent vision loss from NAION are projected to potentially command over $1 million per plaintiff. Mild gastroparesis cases requiring minimal treatment may settle in the $100,000 to $250,000 range. Total manufacturer liability could exceed $2 billion across all claims. These are projections not guarantees — they are based on comparable pharmaceutical mass tort outcomes.

The New Jersey Supreme Court is now allowing GLP-1 vision loss cases to be grouped together in Novo Nordisk's home state of New Jersey. This creates a parallel state-level proceeding alongside the federal MDL — giving plaintiffs in New Jersey additional legal avenues and increasing pressure on Novo Nordisk in their own jurisdiction.

A systemic review of 24 studies found evidence that GLP-1 medications including semaglutide may increase the risk of hair loss. Study authors recommend additional research to better understand the link. This is early-stage evidence but represents a potentially new injury category that plaintiff attorneys are monitoring closely for future litigation.

A wrongful death lawsuit filed April 10, 2026 alleges that Empower Pharmacy supplied a contaminated compounded semaglutide product that contributed to a patient's death in April 2024. The lawsuit alleges the compounded formulation contained chemical impurities or other contaminants that rendered the medication unsafe. This represents a new category of GLP-1 claim targeting compounding pharmacies directly and is being watched closely by the plaintiff bar.

As of May 1, 2026 there are 3,636 lawsuits pending in MDL No. 3094 for GLP-1 gastrointestinal injuries and 86 pending lawsuits in MDL No. 3163 for NAION vision loss. A streamlined direct filing protocol has been established for the vision loss MDL allowing new cases to be filed directly rather than being transferred from other district courts — accelerating the intake of new plaintiffs into the litigation.

A major peer-reviewed study published in JAMA Ophthalmology analyzed over 100,000 veterans with type 2 diabetes and found that patients who started semaglutide had 2.33 times the risk of developing NAION compared to patients on other diabetes medications in the same class. This is the strongest scientific evidence yet in support of NAION claims — the 2.33-fold risk figure meets the Daubert legal standard required for expert testimony in federal court. Legal analysts describe this study as a turning point for NAION litigation.

The FDA issued formal warning letters to multiple GLP-1 telehealth platform operators including MEDVi regarding misleading labeling and safety claims. This regulatory action confirmed the FDA's concern about how these medications were being marketed and monitored without adequate safety oversight — strengthening the legal foundation for patient lawsuits.

The U.S. Judicial Panel on Multidistrict Litigation approved the creation of MDL No. 3163 specifically for GLP-1 NAION vision loss cases. The panel rejected Eli Lilly's request to fold vision loss cases into the existing gastrointestinal MDL — creating a standalone docket before Judge Karen Marston in the Eastern District of Pennsylvania. A separate MDL signals the court recognizes vision loss as a major and distinct category of harm.

GLP-1 litigation grew into one of the largest pharmaceutical mass torts in the United States. Since the start of 2026 alone more than 500 new lawsuits involving GLP-1 drugs have been filed in federal court. A master complaint was filed alleging manufacturers failed to adequately warn patients about significant risks including stomach paralysis, vision loss, pancreatitis, gallbladder disease, and nearly 500 deaths reported in the FDA Adverse Event Reporting System.

Harvard Medical School researchers published the first major peer-reviewed study finding a statistically significant elevated risk of NAION among semaglutide users. This study became the scientific cornerstone for vision loss lawsuits. Combined with the 2026 veterans study confirming a 2.33x risk the NAION scientific record is now among the strongest in pharmaceutical mass tort history.

Early plaintiffs filed individual lawsuits citing severe gastroparesis, intestinal obstruction, and stomach paralysis after Ozempic and Wegovy use. MDL No. 3094 was established in the Eastern District of Pennsylvania in February 2024. Expert witness reports are due mid-2026 with bellwether trial selection anticipated for late 2026 or early 2027.